Raily Aesthetic Medicine International Holdings Limited

SEHK:2135 Stock Report

Market Cap: HK$66.8m

Raily Aesthetic Medicine International Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Raily Aesthetic Medicine International Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth18.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Held Back By Insufficient Growth Even After Shares Climb 37%

Oct 02
Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Held Back By Insufficient Growth Even After Shares Climb 37%

Benign Growth For Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Underpins Its Share Price

Jul 22
Benign Growth For Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Underpins Its Share Price

Revenues Working Against Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) Share Price Following 47% Dive

Apr 22
Revenues Working Against Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) Share Price Following 47% Dive

Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Stock Rockets 39% As Investors Are Less Pessimistic Than Expected

Feb 07
Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Stock Rockets 39% As Investors Are Less Pessimistic Than Expected

Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) Popularity With Investors Is Under Threat From Overpricing

Dec 19
Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) Popularity With Investors Is Under Threat From Overpricing

Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Investors Are Less Pessimistic Than Expected

Aug 22
Raily Aesthetic Medicine International Holdings Limited (HKG:2135) Investors Are Less Pessimistic Than Expected

Statutory Profit Doesn't Reflect How Good Raily Aesthetic Medicine International Holdings' (HKG:2135) Earnings Are

Sep 17
Statutory Profit Doesn't Reflect How Good Raily Aesthetic Medicine International Holdings' (HKG:2135) Earnings Are

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Raily Aesthetic Medicine International Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2135 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024209-32-323N/A
3/31/2024199-32-216N/A
12/31/2023189-32-108N/A
9/30/2023179-26-127N/A
6/30/2023168-20-135N/A
3/31/2023166-18-171N/A
12/31/2022165-16-21-2N/A
9/30/2022178-13-155N/A
6/30/2022191-11-813N/A
3/31/2022190-14-135N/A
12/31/2021188-18-18-2N/A
9/30/2021193-3-103N/A
6/30/202119711-28N/A
3/31/20211818211N/A
12/31/20201654614N/A
9/30/20201610-27N/A
6/30/2020158-4-90N/A
3/31/20201743-29N/A
12/31/201919110417N/A
12/31/2018159181732N/A
12/31/201711317N/A35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2135's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2135's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2135's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2135's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2135's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2135's Return on Equity is forecast to be high in 3 years time


Discover growth companies